GIS:FRA
Gilead Sciences, Inc
113,98Â EUR
arrow_downward
-0,85%(-0,98) 1 zi
13 iul., 12:37:07 GMT+2 · EUR
search
Toate simbolurile
1 zi
5 zile
1 lună
6 luni
Anul curent până azi
1 an
5 ani
MAX
| Simbol | PreÈ› | Modificare | Modificare % |
|---|
insights_autoSe generează principalele statistici pentru GIS...
Deschide
114,12Â EUR
Mare
114,12Â EUR
Mic
113,98Â EUR
Capitalizarea bursieră
162,81Â mld.
Volum mediu
451,00
Volum
225,00
Prețul ridicat pe 52 de săptămâni
132,00Â EUR
Prețul redus pe 52 de săptămâni
92,46Â EUR
Nr. de angajați
17Â K
Deschide
114,12Â EUR
Mare
114,12Â EUR
Mic
113,98Â EUR
Capitalizarea bursieră
162,81Â mld.
Volum mediu
451,00
Volum
225,00
Prețul ridicat pe 52 de săptămâni
132,00Â EUR
Prețul redus pe 52 de săptămâni
92,46Â EUR
Nr. de angajați
17Â K
Subiecte de știri
Din surse de pe web
The Motley Fool
·
acum 1 zi
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.
The Globe and Mail
·
acum 2 zile
Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)
Reuters
·
acum 1 lună
Gilead's drug wins first-ever US approval for deadly liver infection
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Despre Gilead Sciences, Inc
Director executivDaniel O'Day
Angajați17 K
Înființată la22 iun. 1987
SediuFoster City, California, Statele Unite ale Americii
Domeniu-
Sitegilead.com
Conținutul generat de AI poate include greșeli. Află mai multe